Sensus Healthcare, Inc (SRTS)

Price$2.85

Value ScoreB

Growth ScoreD

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-37.30%

Price vs S&P 500 (4W)-27.33%

VGM Score42.50

Market Capitalization$50.87M

P/E Ratio (Annual)9.63x

All Metrics

P/CF (Annual)96.34x

Book Value / Share (Quarterly)$2.77

P/TBV (Annual)2.57x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-14.86%

Cash Flow / Share (Quarterly)$-0.04

Price vs S&P 500 (YTD)-33.30%

Gross Margin (TTM)37.74%

Net Profit Margin (TTM)-34.50%

EPS (TTM)$-0.47

10-Day Avg Trading Volume0.05M

EPS Excl Extra (TTM)$-0.47

Revenue Growth (5Y)23.46%

EPS (Annual)$-0.47

ROI (Annual)-16.05%

Gross Margin (Annual)43.18%

Net Profit Margin (5Y Avg)11.90%

Cash / Share (Quarterly)$1.11

Revenue Growth QoQ (YoY)-59.32%

P/E Normalized (Annual)9.63x

ROA (Last FY)-14.55%

Revenue Growth TTM (YoY)-42.94%

EBITD / Share (TTM)$-0.71

ROE (5Y Avg)12.62%

Operating Margin (TTM)-53.34%

Cash Flow / Share (Annual)$0.02

P/B Ratio1.12x

P/B Ratio (Quarterly)1.44x

Net Income / Employee (Annual)$-128,700

EV / Revenue (TTM)1.44x

Net Interest Coverage (TTM)-100.00x

ROA (TTM)-14.02%

EV / EBITDA (TTM)11.77x

EPS Incl Extra (Annual)$-0.47

Current Ratio (Annual)9.72x

Quick Ratio (Quarterly)4.03x

3-Month Avg Trading Volume0.08M

52-Week Price Return-35.22%

EV / Free Cash Flow (Annual)98.01x

Revenue / Employee (TTM)$375,500

Tangible BV / Share (Quarterly)$2.72

P/S Ratio (Annual)1.85x

Asset Turnover (Annual)0.52x

52-Week High$5.92

Operating Margin (5Y Avg)5.76%

EPS Excl Extra (Annual)$-0.47

CapEx CAGR (5Y)-11.45%

Tangible BV CAGR (5Y)33.89%

26-Week Price Return-21.37%

Quick Ratio (Annual)6.31x

13-Week Price Return-23.13%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)7.27x

Enterprise Value$32.54M

Revenue / Share Growth (5Y)23.62%

Asset Turnover (TTM)0.41x

Book Value / Share Growth (5Y)17.51%

Revenue / Employee (Annual)$458,000

Inventory Turnover (Annual)1.06x

Pretax Margin (Annual)-35.02%

Cash / Share (Annual)$1.34

3-Month Return Std Dev73.69%

Gross Margin (5Y Avg)57.72%

Net Income / Employee (TTM)$-129,500

ROE (Last FY)-16.05%

Net Interest Coverage (Annual)-27.22x

EPS Basic Excl Extra (Annual)$-0.47

P/FCF (TTM)9.45x

Receivables Turnover (TTM)2.09x

EV / Free Cash Flow (TTM)93.64x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.47

Receivables Turnover (Annual)2.13x

ROI (TTM)-15.79%

P/S Ratio (TTM)2.26x

Pretax Margin (5Y Avg)13.47%

Revenue / Share (Annual)$1.68

Tangible BV / Share (Annual)$2.93

Price vs S&P 500 (52W)-63.43%

Year-to-Date Return-22.36%

5-Day Price Return-3.13%

EPS Normalized (Annual)$-0.47

ROA (5Y Avg)10.51%

Net Profit Margin (Annual)-28.09%

Month-to-Date Return-22.17%

Cash Flow / Share (TTM)$-0.04

EBITD / Share (Annual)$-0.61

EPS Growth (3Y)17.62%

Operating Margin (Annual)-37.50%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)100.71x

ROI (5Y Avg)12.62%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.47

P/TBV (Quarterly)1.00x

P/B Ratio (Annual)1.36x

Inventory Turnover (TTM)0.81x

Pretax Margin (TTM)-50.57%

Book Value / Share (Annual)$2.92

Price vs S&P 500 (13W)-32.88%

Beta1.11x

P/FCF (Annual)153.22x

Revenue / Share (TTM)$1.37

ROE (TTM)-15.79%

52-Week Low$2.82

vGradeB

gGradeD

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.16est. -0.13

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.11

4.10

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
SRTSSensus Healthcare, Inc	B	D	D	$2.85
SYKStryker Corporation	C	C	D	$299.46
MMM3M Company	C	F	C	$150.93
BSXBoston Scientific Corp.	C	B	F	$47.98
MDLNMedline Inc. Class A common stock	C	D	D	$35.75
BDXBecton, Dickinson and Co.	B	C	C	$145.33
DXCMDexCom, Inc.	C	B	C	$74.87
RMDResMed Inc.	B	B	D	$186.44
WSTWest Pharmaceutical Services, Inc.	D	C	B	$316.30
SOLVSolventum Corporation	C	D	C	$75.84
PENPenumbra, Inc.	F	C	C	$318.95

About

Sensus Healthcare manufactures superficial radiotherapy (SRT) systems for treating skin cancers and non-cancerous skin conditions. The company's products, including the SRT-100 and SRT-100 Vision platforms, address dermatological applications such as basal cell carcinoma, squamous cell carcinoma, and keloids. Revenue is generated primarily from U.S. customers.